Lisata grants Catalent non-exclusive license for certepetide ADC payload; up to $10.5M milestones

LISATA THERAPEUTICS, INC.

Granted Catalent non-exclusive license to use certepetide as ADC payload in SMARTag platform; Catalent assumes all R&D/commercial costs.
Eligible for up to $10.5M in development milestone payments plus tiered revenue sharing on future sales/partnerships.
Also entitled to portion of sublicense consideration received by Catalent.
Catalent may terminate agreement on 30 days notice; also grants Lisata ROFN for out-licensing of resulting assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.